![](/assets/artwork/1x1-42817eea7ade52607a760cbee00d1495.gif)
666 episodes
![](/assets/artwork/1x1-42817eea7ade52607a760cbee00d1495.gif)
The Signal Daily The Core Team
-
- News
You’ve read The Signal, and you’ve told us you love it. But you asked for more. A deeper dive into one story. So here it is, The Signal daily, an aural deep dive into one interesting story. Tune into The Signal Daily, wherever you listen to your podcasts.
-
The Reality Check on India's Lithium Dreams
Today we look at how new ventures that provide elder care services in India are opening up — as the Indian family structure changes and life expectancies increase. We are also discussing why the initial euphoria around Kashmir’s lithium blocks has now dissipated. Tune in!
-
Apple is Back With an AI Bang
In today’s episode we get into how Japan’s government is planning to launch a dating app to encourage marriage and kids. We also unpack the latest WWDC event and what Apple is doing to be in the AI race. Tune in!
-
EU Parliament is Taking a Right Turn
After a four-day-long electoral process,tThe counting process has begun for the EU Parliamentary elections and already it's triggering political drama as the wind shifts away from mainstream parties. In other news, corrupt officials in Gujarat have reached a new low and are now taking bribes in EMIs as they don't want to lose out on any opportunities. Tune in to this episode for more!
-
Cricket's American Dream
In today's episode we talk about Prime Minister Narendra Modi’s swearing in ceremony and which MPs made it to the final cut. We also dive into the recently concluded EU Parliamentary elections and what’s at stake for Europe.
In other news, India is playing a cricket against Pakistan in a temporary stadium in Long Island in New York. Is this a push into cricket’s American aspirations? Tune in! -
Make Way for Chinese Ozempic
Danish Novo Nordisk’s patent on semaglutide — the active ingredient in weight loss drug Ozempic expires in 2026. In the meantime, Chinese firms have been hard at work, trying to develop at least 15 generic versions of Ozempic and Wegovy. What does that mean for the pharmaceutical market?
In other news, a crisis is brewing at VIP industries as amid declining profits, Nisaba Godrej resigned as an independent director on the board of VIP Industries. What's happening to the legacy suitcase company VIP? Tune in! -
AI Researchers Who Loved and Lost OpenAI
In this episode, we discuss why so many former and current employees of OpenAI are criticising the startup and all the relevant Lok Sabha election-related developments. Tune in!